The Role of Omega 9 Fatty Acids in Lipid Injectable Emulsions (ILE)
July 22, 2020
Time: 4:00 PM– 5:30 PM ET
Omega-9 fatty acids are the differentiating fatty acid in the newest ILE on the US market. Clinicians are challenged to determine the most appropriate ILE for their patient. To do so it is essential to have a strong understanding of the attributes of the key fatty acids: omega- 3, 6 and 9 and the literature that support their safety and efficacy. This webinar will focus on providing the clinician an understanding of omega-9 fatty acids and the literature that supported its FDA approval in ILE products.
- Identify the characteristics of omega-9 fatty acids
- Outline how omega-9 fatty acids differ from omega- 3 and 6 fatty acids and what benefit or disadvantage they may bring to an ILE
- Summarize the clinical evidence supporting the efficacy and safety of the omega-9 fatty containing ILEs
Understanding Omega- 9 Fatty Acids: How are they Unique?
Gary P. Zaloga, MA, MD, Chief Medical Officer, MedSciHealth Consultants, Bradenton, Florida
What is the clinical evidence for Omega-9 fatty acids containing ILE?
Mark DeLegge, MD, DeLegge Medical, Charleston, South Carolina
Moderator: Todd W. Canada, PharmD, BCNSP, BCCCP, FASHP, FTSHP, FASPEN, Clinical Pharmacy Services Manager & Nutrition Support Team Coordinator, University of Texas MD Anderson Cancer Center, Houston, TX
Free non-CE webinar.
This webinar is supported by